公开(公告)号：EP2603204A2

公开(公告)日：2013-06-19

申请号：EP11749878.2

申请日：2011-08-09

申请人： Novacta Biosystems Limited

发明人： APPLEYARD, Antony Nicholas ,  WADMAN, Sjoerd Nicolaas

IPC分类号： A61K9/19 ,  A61K38/10 ,  A61K47/26 ,  A61K9/00

CPC分类号： A61K9/0019 ,  A61K9/19 ,  A61K38/164 ,  A61K47/26

摘要： Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and/or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates.

公开(公告)号：EP2531519A1

公开(公告)日：2012-12-12

申请号：EP11705953.5

申请日：2011-02-01

申请人： Novacta Biosystems Limited

发明人： WADMAN, Sjoerd Nicholaas ,  APPLEYARD, Antony Nicholas

IPC分类号： C07K7/08 ,  A61P31/04 ,  A61K38/10

CPC分类号： A61K38/10 ,  C07K7/08

摘要： Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant
Staphylococcus aureus (MRSA) infection. The salts have an aqueous solubility of 2.5 mg/mL or more.